What is OncoResponse?
OncoResponse is a biotechnology firm dedicated to discovering novel therapeutic targets and developing fully human monoclonal antibodies for cancer treatment. The company leverages its proprietary human antibody platform to identify candidates aimed at treating cancer and extending cures to patients who do not respond to conventional immunotherapy. Its focus on innovative antibody discovery positions it within the competitive landscape of oncology drug development.
How much funding has OncoResponse raised?
OncoResponse has raised a total of $203.2M across 10 funding rounds:
Private Equity
$29.5M
Series A
$9.5M
Series B
$40M
Debt
$150K
Debt
$416K
Series C
$40.6M
Debt
$50M
Other Financing Round
$14M
Grant
$13M
Other Financing Round
$6M
Private Equity (2015): $29.5M, investors not publicly disclosed
Series A (2015): $9.5M led by Canaan Partners, MD Anderson, and ARCH Venture Partners
Series B (2018): $40M, investors not publicly disclosed
Debt (2020): $150K featuring PPP
Debt (2021): $416K backed by PPP
Series C (2021): $40.6M with participation from Canaan Partners, 3B Future Health Fund, Magnetar Group, Redmile Group, BERING CAPITAL, Yonjin Venture, ARCH VENTURE PARTNERS, Qatar Investment Authority, and RiverVest Venture Partners
Debt (2022): $50M led by Oxford Finance
Other Financing Round (2023): $14M supported by ARCH Venture Partners, RiverVest Venture Partners, and Canaan Partners
Grant (2023): $13M featuring Cancer Prevention and Research Institute of Texas
Other Financing Round (2025): $6M, investors not publicly disclosed
Key Investors in OncoResponse
Canaan Partners
Canaan Partners is a venture capital firm with a focus on early-stage technology and healthcare companies, including biopharma. They support founders from seed through growth stages, indicating a strategic interest in OncoResponse's development.
ARCH Venture Partners
ARCH Venture Partners is a prominent venture capital firm specializing in life sciences and advanced technology. Their involvement suggests a commitment to innovative scientific ventures and a belief in OncoResponse's platform technology.
RiverVest Venture Partners
RiverVest Venture Partners is a venture capital firm dedicated to building life science companies that address significant unmet medical needs. Their investment highlights a focus on impactful therapeutic advancements in healthcare.
What's next for OncoResponse?
The recent major strategic investment and enterprise-level funding indicate a pivotal growth phase for OncoResponse. This capital infusion is expected to accelerate the advancement of its pipeline, potentially enabling further clinical trials, expanding research and development capabilities, and forging strategic partnerships. The company's trajectory suggests a strong focus on translating its platform discoveries into viable therapeutic solutions for a broad patient population.
See full OncoResponse company page
